The short answer
A universal omega-3 fatty acids restriction or timing change with nabumetone is not established. Review the exact formulation and your bleeding risks rather than assuming all omega-3 products behave alike.
What this answer covers
Oral omega-3 fatty acids with oral nabumetone tablets. EPA/DHA fish oil, purified EPA, ALA and foods are distinct; nabumetone is a prodrug converted to 6MNA.
- Supplement or preparation
- Omega-3 Fatty Acids
- Medication ingredient
- nabumetone
A large fish-oil trial did not show more bleeding
In a randomized study of 1516 cardiac-surgery patients, a defined EPA/DHA fish-oil regimen did not increase major perioperative bleeding compared with placebo. This challenges a blanket claim that every fish-oil exposure increases bleeding. It did not establish the effect of chronic co-use with nabumetone.
Nabumetone has its own safety profile
Nabumetone is converted in the body to an active metabolite called 6MNA. Its label reports little platelet effect and no bleeding-time change in a short study using 1000 mg daily, but serious GI bleeding and ulcer warnings remain. This profile differs from other NSAIDs and does not prove either safety or harm from a particular supplement. The surgery study is not a reason to use nabumetone around coronary bypass surgery, where NSAIDs are contraindicated.
Identify the actual omega-3 formulation
Check EPA and DHA amounts rather than total oil weight, and tell your pharmacist whether the product is a prescription preparation, a mixed supplement or another fatty acid such as ALA. The fish-oil trial does not establish equivalent effects for purified EPA or every product sold as omega-3.
There is no established special schedule
The inspected evidence does not show that nabumetone changes your nutritional omega-3 requirement or requires a fixed separation interval. If a product was prescribed for a separate condition, ask its prescriber before changing it. Review bleeding history and other medicines, and report unusual bleeding or persistent GI symptoms.
Evidence and practical considerations
Timing & monitoring
A universal bleeding, supplement-need or timing change for omega-3 fatty acids during nabumetone treatment has not been established.
- Exact scope
- Oral omega-3 fatty acids with oral nabumetone tablets. EPA/DHA fish oil, purified EPA, ALA and foods are distinct; nabumetone is a prodrug converted to 6MNA. with Exact nabumetone RxCUI 31448 IN. Oral nonacidic prodrug converted in the liver to active 6MNA; 6MNA is not substituted as a separate medication identity. No automatic equivalence to aspirin, other NSAIDs or other routes.
- Medication form and route
- Oral
What remains uncertain
- Large EPA/DHA perioperative trial is useful counterevidence but not exact nabumetone co-use. CABG setting is not an endorsement of perioperative NSAID use. No universal transfer across omega-3 formulations.
Factors that may matter: Exact preparation and dose; Fasting versus fed dosing; Bleeding and ulcer history; Other medicines.
Read the supporting source summaries
Source 1: Current prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Prescription oral oral nabumetone tablets users; short human pharmacology studies where described.
Prodrug converted to 6MNA. One-week 1000 mg daily study found little platelet aggregation effect and no bleeding-time change; naproxen comparator differed. GI bleeding and renal warnings remain.
How this applies: Exact current product label. Exact nabumetone RxCUI 31448 IN. Oral nonacidic prodrug converted in the liver to active 6MNA; 6MNA is not substituted as a separate medication identity. No automatic equivalence to aspirin, other NSAIDs or other routes.
Short surrogate studies do not establish long-term GI safety or exact supplement co-use. Potassium-specific precaution uses separately identified potassium-label NSAID guidance, not an invented drug-specific rate.
Source 2: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 1516 cardiac-surgery patients in the randomized OPERA trial bleeding analysis.
Major perioperative bleeding was not increased versus placebo; odds ratio 0.81, 95% CI 0.53-1.24. Fewer transfusion units were used.
How this applies: Indirect for oral nabumetone tablets co-use; exact preparation and endpoint retained.
Abstract-only for this capture. Not a trial of chronic oral nabumetone tablets co-use. Cardiac surgery is a different setting, and NSAIDs are contraindicated around CABG. Does not represent purified EPA, ALA or all doses.
Source 3: Medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Terminology.
nabumetone is IN.
How this applies: Exact identity.
Not clinical evidence.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: 94fcc0e82dcad6f2
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.